摘要
目的:探讨骨髓增生异常综合征(myelodysplastic syndromes,MDS)中CD96和CD123的表达及其与预后的关系。方法:选取经骨髓穿刺和外周血检查确诊为MDS的患者89例作为MDS组,另选取无血液系统疾病者20例作为对照组,对所有受试者进行骨髓穿刺,并提取骨髓中的单个核细胞,对CD34^+CD38^-CD123^+细胞和CD34^+CD38^-CD96^+细胞进行计数。将MDS组患者按照危险度分组,并给予相应治疗措施,观察治疗效果。结果:MDS组患者骨髓单个核细胞中CD34^+细胞和CD34^+CD38^-细胞所占比例显著高于对照组(P<0.05),CD34^+CD38^-CD123^+细胞和CD34^+CD38^-CD96^+细胞在CD34^+CD38^-中所占比例显著高于对照组(P<0.05),且危险度越高,比例越高;低危-中危1亚组中,CD123^-和CD96^-患者的完全缓解(CR)和缓解率(RR)均显著高于CD123^+和CD96^+患者;中危2-高危亚组中,CD123^-患者的RR显著高于CD123^+患者(P<0.05),CD96^-患者的CR显著高于CD96^+患者。结论:MDS患者骨髓单个核细胞内CD34^+细胞分化存在异常,且存在有CD123和CD96高表达的情况,这可能是MDS患者出现造血干细胞恶性克隆的原因。
Objective： To explore the relationship between expression of CD96 and CD123 and prognosis of patients with myelodysplastic syndrome（ MDS）. Methods： Eight-nine MDS patients（ MDS group） and 20 persons without hematologic disease as controls（ Control group） were enrolled. The patients were grouped by the risk. All participants received bone marrowbiopsy. Mononuclear cells were extracted,CD34^＋CD38^-CD123^＋and CD34^＋CD38^-CD96^＋cells were counted by using flowcytometry. Expressions of 2 type cells in control group,MDS group and its subgroups were analyzed. Results： The proportion of CD34^＋cells and CD34^＋CD38^-cells in mononuclear cells of patients in MDS group was higher than in control group（ P〈0. 05）. The proportions of CD34^＋CD38^-CD123^＋cells and CD34^＋CD38^-CD96^＋cells in CD34^＋CD38^-cells were significantly higher than that in control group（ P〈0. 05） and the proportion increased with the risk. In the low-and middle-risk group,the rates of complete remission（ CR） and partial remission（ PR）of patients with CD123^-and CD96^-were higher than those in patients with CD123^＋and CD96^＋; in the middle-2 and high risk patients,the PR of patients with CD123^-was higher than that in patients with CD123^＋（ P〈0. 05）. The CR rate of patients with CD96^-was higher than that of patients with CD96^＋（ P〈0. 05）. Conclusion： The differentiation of CD34^＋cells in bone marrowof MDS patients is abnormal,and the high expression of CD123 and CD96 cells existes.These findings may partially explain the cause of hematopoietic stem cell malignant clone in MDS patients.
出处
《中国实验血液学杂志》
CAS
CSCD
北大核心
2018年第1期208-212,共5页
Journal of Experimental Hematology
基金
黑龙江省自然基金面上项目(H201352)
